Topiramate Tablet
Product Images NDC 80425-0195

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 80425-0195). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

Chemical structure of topiramate, depicted as a detailed molecular diagram showing its carbon, hydrogen, oxygen, nitrogen, and sulfur atoms arranged in its functional groups.*

FDA Label Image

Label 2 (Label 2)

Topiramate 50 mg tablet packaging label by Advanced Rx Pharmacy of Tennessee, LLC, Nashville, TN. Contains barcode, storage instructions at 20°-25°C (68°-77°F), lot number 90TOP0501023, expiration date 10/31/2023, and NDC 80425-0195-03. Labels include a comparison to NDC 69097-0123-03 and lists Cipla USA, Inc. as manufacturer.*

FDA Label Image

Label 1 (Lable 1)

Topiramate 50 mg tablet label from Advanced Rx Pharmacy of Tennessee, LLC, Nashville, TN. The label includes the product name, dosage strength, dosage form, and NDC number 80425-0195-02. It also references comparison to Topamax and includes lot number 60TOP50723 with expiration date 7/31/2023. Storage instructions and manufacturer Cipla USA, Inc. details are provided.*

FDA Label Image

Fig 1 (Fig 1)

A line graph showing cumulative rates for time to first seizure over a period of 0 to 500 days. It compares two groups receiving Topiramate at doses of 50 mg/day and 400 mg/day, with the higher dose showing a lower cumulative seizure rate. The graph includes sample sizes for each group and a statistical p-value of 0.0002.*

FDA Label Image

Fig 2 (Fig 2)

A bar chart showing the change from baseline to double-blind phase in average weekly migraine period relief (±SEM) for placebo and three doses of Topamax (50 mg/day, 100 mg/day, 200 mg/day). It compares results from Study 10 and Study 11, indicating increasing migraine relief with higher doses of Topamax, with statistical significance marked for 100 mg/day and 200 mg/day doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.